| Disease | A 90-DAY, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSED THE EFFICACY OF A GINSENG/GINKGO COMBINATION ON COGNITIVE AND PHYSICAL FUNCTIONS IN HEALTHY VOLUNTEERS WITH NEURASTHENIC COMPLAINTS. SIXTY-FOUR HEALTHY VOLUNTEERS (AGED 40 TO 65 YEARS),
SELECTED ON THE BASIS OF FULFILLING THE ICD-10 F48.O CRITERIA FOR NEURASTHENIA, WERE ASSIGNED RANDOMLY TO FOUR EQUAL DOSING GROUPS, RECEIVING 80, 160, OR 320 MG OF THE COMBINATION B.I.D. OR PLACEBO. ASSESSMENTS WERE PERFORMED ON THE DAY BEFORE
DOSING, AND AGAIN AT DAYS 1, 30, AND 90 AT 1 HOUR AFTER MORNING DOSE AND 1 HOUR AFTER THE AFTERNOON DOSE. THE ASSESSMENTS INCLUDED THE COGNITIVE DRUG RESEARCH (CDR) COMPUTERIZED ASSESSMENT SYSTEM, THE VIENNA DETERMINATION UNIT, CYCLE ERGOMETRY
AND VARIOUS QUESTIONNAIRES. THE TREATMENTS WERE WELL TOLERATED BY ALL VOLUNTEERS. ON DAY 90 AT 1 HOUR POST MORNING DOSING, DOSE-RELATED IMPROVEMENTS WERE SEEN ON THE CDR TESTS, THE 320 MG DOSE BEING SIGNIFICANTLY SUPERIOR TO PLACEBO. THESE
EFFECTS, HOWEVER, WERE REVERSED 1 HOUR AFTER THE AFTERNOON DOSE, POSSIBLY SUGGESTING THAT A LONGER INTER-DOSING INTERVAL WOULD BE PREFERABLE. |